Merck Price to Sales Ratio 2010-2023 | MRK

Historical PS ratio values for Merck (MRK) over the last 10 years. The current P/S ratio for Merck as of April 19, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-19 125.78 5.33
2023-12-31 108.33 $23.61 4.59
2023-09-30 101.56 $23.31 4.36
2023-06-30 113.07 $22.93 4.93
2023-03-31 103.55 $22.75 4.55
2022-12-31 107.26 $23.34 4.60
2022-09-30 82.71 $23.23 3.56
2022-06-30 86.87 $22.53 3.86
2022-03-31 77.55 $21.27 3.65
2021-12-31 71.80 $19.19 3.74
2021-09-30 69.71 $17.47 3.99
2021-06-30 71.54 $16.59 4.31
2021-03-31 70.31 $15.79 4.45
2020-12-31 73.96 $16.34 4.53
2020-09-30 74.40 $14.34 5.19
2020-06-30 68.86 $14.85 4.64
2020-03-31 67.97 $15.71 4.33
2019-12-31 79.71 $15.08 5.29
2019-09-30 73.27 $17.50 4.19
2019-06-30 72.50 $16.56 4.38
2018-12-31 65.20 $15.72 4.15
2018-09-30 60.10 $15.41 3.90
2018-06-30 51.07 $15.54 3.29
2018-03-31 45.47 $15.44 2.94
2017-12-31 46.57 $15.35 3.03
2019-03-31 71.44 $14.96 4.78
2017-09-30 52.54 $14.43 3.64
2017-06-30 52.22 $14.43 3.62
2017-03-31 51.39 $14.35 3.58
2016-12-31 47.27 $14.27 3.31
2016-09-30 49.73 $14.24 3.49
2016-06-30 45.57 $14.01 3.25
2016-03-31 41.51 $13.91 2.98
2015-12-31 41.08 $13.87 2.96
2015-09-30 38.08 $13.85 2.75
2015-06-30 43.52 $13.93 3.12
2015-03-31 43.60 $14.20 3.07
2014-12-31 42.74 $14.37 2.97
2014-09-30 44.28 $14.57 3.04
2014-06-30 42.89 $14.67 2.92
2014-03-31 41.78 $14.62 2.86
2013-12-31 36.54 $14.66 2.49
2013-09-30 34.45 $14.70 2.34
2013-06-30 33.31 $14.70 2.27
2013-03-31 31.41 $15.05 2.09
2012-12-31 28.82 $15.37 1.88
2012-09-30 31.44 $15.53 2.02
2012-06-30 28.83 $15.69 1.84
2012-03-31 26.23 $15.59 1.68
2011-12-31 25.48 $15.50 1.64
2011-09-30 21.83 $15.40 1.42
2011-06-30 23.29 $15.10 1.54
2011-03-31 21.55 $14.82 1.45
2010-12-31 23.26 $14.73 1.58
2010-09-30 23.51 $15.29 1.54
2010-06-30 22.10 $14.57 1.52
2010-03-31 23.35 $13.74 1.70
2009-12-31 22.61 $12.65 1.79
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $318.604B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67